ITPA and tuberculosis: Detailed biochemical and modeling data with these mutants will provide a platform for protein engineering experiments to continue improving ITPase activity and/or substrate discrimination with the aim of developing therapies to reverse thiopurine toxicity, neurological disorders, TB susceptibility and emerging ITPA-related disorders in patients affected by ITPA polymorphism.